Strategic Advocates’s Astera Labs ALAB Stock Holding History

Strategic Advocates’s Portfolio ALAB Stock Details ALAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$58K	Buy	120 +109	+991%	+$28.9K	0.22%	78
2026 Q1	$1.21K	Buy	+11	New	+$1.57K	0.01%	229

Other funds holding ALAB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Strategic Advocates's ALAB Position: Q2 2026 in Review

Strategic Advocates increased its Astera Labs (ALAB) stake by 991% in Q2 2026, buying an estimated $28.9K and bringing the position to 120 shares worth $58K. The position accounts for 0.22% of the portfolio, ranked #78.

Strategic Advocates first reported a position in ALAB in Q1 2026 and has held it in 2 quarters since. 988 funds tracked by Wall St. Rank hold ALAB as of Q2 2026.

Strategic Advocates held 120 shares of Astera Labs worth $58K as of Q2 2026.
Strategic Advocates bought 109 Astera Labs shares in Q2 2026, an estimated $28.9K.
Astera Labs made up 0.22% of Strategic Advocates's portfolio in Q2 2026, its #78 holding.
Strategic Advocates first reported a position in Astera Labs in Q1 2026 and has held it in 2 quarters since.
988 funds tracked by Wall St. Rank held Astera Labs as of Q2 2026.

Based on Strategic Advocates's 13F filing for Q2 2026, filed 13 Aug 2026.